Clinical

Dataset Information

0

Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer


ABSTRACT: Based on the pervious data, aflibercept in combination with FOLFIRI is one of the effective 2nd line treatment option in advanced colorectal cancer. In this study, we prospectively assess the efficacy of 2nd line aflibercept in combination with FOLFIRI in advanced colorectal cancer in terms of progression-free survival. We further assess the efficacy according to the type of 1st line treatment. plasma biomarker study (HGF, VEGF-A, VEGF-D, IFN-γ, Angiopoietin-2, sICAM-1, sVCAM-1, TIMP-1, PIGF (HS), IL-6 (HS), IL-8 (HS), sNeuropilin-1, Thrombospondin-2 , Osteopontin , sVEGFR1, sVEGFR2, sVEGFR3) , overall survival (OS)OS, objective response rate (ORR), and safety are also assessed as the 2ndary objectives.

DISEASE(S): Recurrent Or Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2371673 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2289692 | ecrin-mdr-crc
2013-09-01 | E-GEOD-50519 | biostudies-arrayexpress
2024-02-08 | PXD017863 | Pride
2024-05-21 | PXD021501 | Pride
2013-09-01 | GSE50519 | GEO
2023-02-17 | E-MTAB-12569 | biostudies-arrayexpress
2013-03-15 | E-GEOD-36537 | biostudies-arrayexpress
2024-09-02 | BIOMD0000000544 | BioModels
2024-09-02 | BIOMD0000000543 | BioModels
2014-06-01 | E-GEOD-47621 | biostudies-arrayexpress